Evofem Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 27, 2024

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Opening this filing…